R. Klamroth, A. Bonner, S. Yan, P. Monahan, K. Szafranski, M. Herepath, X. Zhang, K. Gomez
{"title":"基因疗法etranacogene dezaparvovec (CSL222)与延长半衰期因子IX治疗重度或中重度血友病B的间接治疗比较","authors":"R. Klamroth, A. Bonner, S. Yan, P. Monahan, K. Szafranski, M. Herepath, X. Zhang, K. Gomez","doi":"10.1055/s-0042-1760567","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":217767,"journal":{"name":"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark","volume":"14 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B\",\"authors\":\"R. Klamroth, A. Bonner, S. Yan, P. Monahan, K. Szafranski, M. Herepath, X. Zhang, K. Gomez\",\"doi\":\"10.1055/s-0042-1760567\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":217767,\"journal\":{\"name\":\"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark\",\"volume\":\"14 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0042-1760567\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1760567","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B